Aktie A2DU8Q PREVECEUTICAL MEDICAL INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen PreveCeutical Medical Inc.

Aktien

A2DU8Q

CA74141E1043

PREV

Verzögert Canadian Securities Exchange
Andere Börsenplätze
 15:55:43 15.05.2024 		% 5 Tage % 1. Jan.
0,025 CAD 0,00 % Intraday Chart für PreveCeutical Medical Inc. 0,00 % 0,00 %
2023 PreveCeutical Medical Inc. beginnt mit der Vorbereitung einer präklinischen Studie für seine Krankheiten und erhält den Proof-Of-Concept für sein duales Gentherapieprogramm CI
2023 PreveCeutical Medical Inc. meldet Ergebnis für das dritte Quartal und die neun Monate bis zum 30. September 2023 CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
PreveCeutical Announces Management Cease Trade Order
PreveCeutical Medical Inc. announced that it expects to receive CAD 0.25 million in funding
PreveCeutical Medical Inc. Initiates Preparation of Preclinical Study for Its Diseases & Obtains Proof-Of-Concept Dual Gene Therapy Program
PreveCeutical Medical Prepares For Proof of Concept Preclinical Study For Diabetes, Obesity Dual Gene Therapy Program
PreveCeutical Medical Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
PreveCeutical & Endosane Announce Update on Intranasal CBD Application
PreveCeutical Medical Inc. and Endosane Pharmaceuticals GmbH Announces Innovative Preclinical Approaches to Assess Brain Availability of CBD and Pharmacologically Relevant Doses Following Intranasal CBD Application
PreveCeutical Medical Inc. Showcases Dynamic Evolution in AI Strategy
PreveCeutical Medical : Showcases Dynamic Evolution in AI Strategy
PreveCeutical Engages New to the Street for Production and Broadcasting Services
PreveCeutical Medical : Engages New to the Street for Production & Broadcasting Services
PreveCeutical Medical Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
PrevCeutical Medical Provides Update
PreveCeutical Medical Inc. Files Cyclic Peptides and Uses Thereof in EU and Australia
PreveCeutical Medical : Files Cyclic Peptides And Uses Thereof in the EU and Australia
PreveCeutical Files Two Family Patents of Sol-Gel Cannabinoid Formulation and Antiviral Use and Cyclic Peptides and Uses Thereof
PreveCeutical Medical Inc. Files Two Family Patents of Sol-Gel Cannabinoid Formulation and Antiviral Use & Cyclic Peptides and Uses Thereof
PreveCeutical Medical : Files Two Family Patents of Sol-Gel Cannabinoid Formulation And Antiviral Use & Cyclic Peptides And Uses Thereof
Preveceutical Medical Inc. Furthering the Progress of Its Patent Family Directed to Sol-Gel
PreveCeutical Medical : Sol-Gel and Uses thereof Patent Update
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2DU8Q Aktie
  4. Nachrichten PreveCeutical Medical Inc.
  5. Andere Sprachen